Clinically, it has been observed that ABC-DLBCL patients are less responsive to standard immuno-chemotherapy than other DLBCL subtypes, the NF-κB may be responsible for this, due to its ability of antagonizing the tumor suppressor activity of chemotherapeutic agents. The gene discussed is NFKB1; the disease is neoplasm.